Digital Medicine

A New Category of Therapy

Managing your medicine each day is not always easy. 50% of prescribed medication is not taken as directed, resulting in unnecessary escalation of conditions and therapies and higher costs to health systems.

We believe this is a problem with the product, not the patient. We believe that by providing the right technology to individuals who deliver and receive healthcare, we can build a more effective health system focused on daily care and new information-based business models.

We believe that by providing the right technology to individuals who deliver and receive healthcare, we can build a more effective health system focused on daily care and new information-based business models.

Press Office

For product images, video footage and interview requests, please contact the Proteus Press Office. Media requests only.

Press Releases

Investor Resources

Coming Soon

Meet our Executive Team

Our executive team and board of directors guide Proteus based on their depth of expertise across life sciences, consumer technology and capital markets

Andrew Thompson

Co-Founder, CEO

Andrew Thompson is co-founder, president and chief executive officer of Proteus Digital Health. His vision for Digital Medicine is focused on expanding global access to care, dramatically increasing the value delivered by drugs and creating a sustainable model for innovation that leverages the cell phone in everyone’s pocket.

Andrew serves on the World Economic Forum Technology Pioneers selection committee and he is also a Co-Founder and Board member of Summit Schools, a leading Charter High School organization with a unique digital platform.  Andrew is active in digital humanities innovation with Stanford University and Cambridge University and a Co-Founder of Parker Library Online – the leading destination for digital medieval studies.

He holds masters degrees in Engineering (Cambridge), Education (Stanford) and Business (Stanford GSB) and has a successful 25 year track record starting and building technology based healthcare companies in Silicon Valley.

George Savage, M.D.

Co-Founder, Chief Medical Officer

George Savage is chief medical officer and co-founder of Proteus Digital Health, and formerly the company’s vice president of research and development.

Named by PharmaVoice as one of the 100 most inspiring people in the pharmaceutical industry, his focus is on developing the clinical and economic evidence needed to secure global regulatory approvals and spur widespread adoption of Proteus’ ingestible sensor platform.

Dr. Savage holds a B.S. in biomedical engineering from Boston University, an M.D. from Tufts University School of Medicine and an M.B.A. from Stanford University Graduate School of Business

Mark Zdeblick, Ph.D.

Co-Founder, CTO

Mark Zdeblick is chief technology officer and co-founder of Proteus Digital Health, and leads the group innovating on our technology. Previously, Mark served as the chief technology officer for the optical switch group at K2 Optronics and served as founder and chief technology officer of Redwood Microsystems.

Mark holds a B.S. in civil engineering and a B.A. in architecture, both from the University of Illinois, and an M.S. in aeronautics and astronautics and Ph.D. in electrical engineering from Stanford University.

David O'Reilly

Chief Product Officer

David O’Reilly is chief product officer of Proteus Digital Health and leads the company’s product development, business development and corporate strategy. Prior to joining Proteus, David was president of Catalyst Biosciences and chief business officer and member of the founding management team at Iconix Biosciences (acquired by Entelos).

David is a graduate of Wesleyan University and the Harvard Business School, where he received an M.B.A. with Distinction.

Steve Fieler

Chief Financial Officer

Steve Fieler is chief financial officer of Proteus Digital Health. Prior to joining Proteus, he was chief financial officer for Hewlett Packard’s software division, a business with $4 billion in annual revenue.

Steve was previously HP’s vice president investor relations and held several other leadership positions in corporate development and operations at the company.

Steve holds a BA in Economics and International Relations from Brown University and an MBA from Harvard Business School.

Donald Cowling

Head of Commercial Programs

Donald Cowling is head of commercial programs at Proteus Digital Health and leads the company’s commercial organization and European operations.

Prior to joining Proteus, he was a senior vice president, Western Europe at Merck Serono, and managing director of Merck operations in the UK.

Donald holds a BSc in Biochemistry, has a finance background with Pricewaterhouse Coopers, and a mini-MBA from Harvard & MIT.

Ben Costello, Ph.D.

Head of Operations

Ben Costello is head of operations at Proteus Digital Health and leads the company’s manufacturing, supply chain and logistics. Previously, Ben was the director of microtechnology at DiCon Fiberoptics, where he developed the world’s best-selling fiberoptic MEMS product.

Ben holds a B.S. in electrical engineering from MIT and a Ph.D. from the joint University of California, Berkeley/University of California, San Francisco program in bioengineering.

Markus Christen, Ph.D.

Head of Global Development

Markus Christen is head of global development at Proteus Digital Health and drives program and alliance management. Prior to joining Proteus, Markus was the global head of strategy, business development and M&A for molecular diagnostics and eHealth at Novartis Pharma AG.

Markus holds a Ph.D. in Chemistry from Warwick University

Tony Levitan

Head of People

Tony Levitan is head of people at Proteus Digital Health, where he is responsible for all aspects of the company’s efforts to create a strategic advantage through its people. Tony co-founded Internet pioneer Egreetings Network (IPO, acquisition) along with two other Silicon Valley companies.

Tony has an M.B.A from the Graduate School of Business at Stanford University, a B.A. in Asian Studies from Hamilton College, and studied Mandarin language at Guo Yu Ri Bao in Taipei, Taiwan.

Meet our Board of Directors

Our executive team and board of directors guide Proteus based on their depth of expertise across life sciences, consumer technology and capital markets

Frank Fischer

Chairman

Frank Fischer has more than 25 years of senior management experience in the medical device industry.

The president and CEO of the biomedical device company NeuroPace, he has served on the company’s board since 1998 and joined the company as its chief executive officer in January 2000.

Frank continues to serve on the boards of several privately held medical device companies.

Robert Epstein, M.D., M.S.

Board Member

Dr. Robert Epstein was most recently president of the Medco-UBC Division and chief R&D officer of Medco Health Solutions, Inc.

Dr. Epstein is the former president of the International Society of Pharmacoeconomics and Outcomes Research, and has served on the Board of Directors of the Drug Information Association.

He has published more than 50 peer-reviewed medical articles and book chapters, and serves as a reviewer for several influential medical journals.

Alan J. Levy, Ph.D.

Board Member

Alan Levy is a venture partner with Frazier Healthcare Ventures and has over 30 years of senior management experience in the medical device industry.

He serves on the board of Intuitive Surgical, a publicly held company, and several other privately held medical device firms.

Myrtle Potter

Board Member

Myrtle is CEO of Myrtle Potter and Company. A best-selling author, Myrtle has dedicated three decades to serving the healthcare needs of millions of consumers.

She serves on the board of Everyday Health, Liberty Mutual and is on the board of Trustees of the University of Chicago. Myrtle was president and chief operating officer of Genentech, president at Bristol-Myers Squibb and a vice president at Merck.

Ryan Schwarz

Board Member

Ryan Schwarz is a managing director at The Carlyle Group where he leads the healthcare investing practice for the company’s U.S. Venture & Growth Capital Group, specializing in medical devices, medical technology and healthcare information technology.

Ryan serves on the boards of AcuFocus, Lipsonix, NeoVista, Cellutions and PixelOptics.

Charles Songhurst

Board Member

Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He runs an investment portfolio and the Songhurst Group which holds asset in a variety of private companies.

Previously, Charles ran corporate strategy for Microsoft and focused on partnering and M&A.

Jon Symonds, CBE

Board Member

Jon Symonds, CBE, is chairman of HSBC Holdings plc. Jon is Chairman of Innocoll, non-executive director of Proteus Digital Health Inc and non-executive director of Genomics England. Jon was CFO of Novartis AG from 2009 to 2013.

Immanuel Thangaraj

Board Member

Immanuel Thangaraj is a managing director at Essex Woodlands, a leading health care venture capital and growth equity company.

With over 15 years of experience in operations and venture capital, he currently serves on the boards of CBR Systems, Acura Pharmaceuticals, Clear Vascular, Medlogics, and Sound ID.

Partners

We are working with our strategic partners to apply our platform in selected CNS, clinical trial and elder care settings.

  • With Otsuka, we will deliver commercial digital health products in one area of CNS therapy.

  • In partnership with Oracle, we are commercializing InForm Medication Adherence Insights to help trial sponsors optimize clinical trials and increase potential for trial success. Learn more here.

  • In partnership with Novartis, we are developing and commercializing digital health products in the fields of organ transplantation and diseases effecting the elderly.

Otsuka

With Otsuka, we will deliver commercial digital health products in one area of CNS therapy.

Oracle

In partnership with Oracle, Proteus is commercializing InForm Medication Adherence Insights to help trial sponsors optimize clinical trials and increase potential for trial success. Learn more here.

Novartis

In partnership with Novartis, we are developing and commercializing digital health products in the fields of organ transplantation and diseases effecting the elderly.

Offerings

Our platform is being applied in at-risk patient management, elite athletics and clinical trials.

Proteus Discover

Proteus Discover integrates therapy with analytics for at-risk patient management and is designed to help physicians identify the underlying cause for a patient’s lack of control within four weeks. Proteus Discover is initially targeted at patients with complex cardiovascular and metabolic disease.

Oracle

In late 2014, Oracle and Proteus launched Oracle Health Sciences InForm Medication Adherence Insights to help trial sponsors optimize clinical trials and increase potential for trial success. Learn more here.